COMMUNITY
Challenges in Cardiovascular Epidemiology Digital Forum
The Epidemiology Forum facilitates an active and highly engaged discussion of the future of epidemiology in general and the study of cardiovascular diseases in particular. There have been numerous discussions on several critical topics. In a recent post on cost-effective study design, the insightful comments included: - Instead of thinking about a less-expensive study design, we might think about how technology will affect the study designs we have, and potentially reduce costs.
- To encourage innovative research, a separate funding mechanism should be established for discovery epidemiology.
- Crowd-sourcing designs should be explored by epidemiologists and biases carefully evaluated.
See what else others are saying and join the conversations. |
RESOURCE
Special Report: Cardiovascular Pharmacogenomics
The NHLBI convened a working group in January 2011 to provide recommendations to guide informed decisions on research directions and priorities in the field of cardiovascular pharmacogenomics (the study of variations of DNA and RNA characteristics related to drug response). The report was published in the April 2012 issue of the Journal of the American Heart Association. View the report on cardiovascular
pharmacogenomics. |
DIRECTOR'S CORNER
New Global Research Projects To Reduce Impact of Hypertension
The Global Alliance for Chronic Diseases (GACD) held a Secretariat Launch Event at University College London on June 11, 2012. At the event, NIH Director Dr. Francis Collins announced that the NIH and three other member organizations of the GACD are supporting research projects on how best to implement effective approaches to prevent and control hypertension (high blood pressure) in 15 low- and middle-income countries. This significant initiative, which is the first coordinated funding effort among GACD members, includes 14 community-based research projects.
Learn more about the global research projects.
NEWS FROM AN NHLBI-FUNDED INSTITUTION
Statins Shown To Cause Fatigue
In a randomized trial of more than 1,000 adults, researchers at the University of California, San Diego, found that people taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both. The researchers suggest that these findings should be taken into account by doctors when weighing risk versus benefit in prescribing statins.
Learn more about this NHLBI-funded study.
Learn more about treatment for high blood cholesterol.
Please note that the photos on this page of the past and future signs and the bottle and pills are not for public use.
